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Abstract
The gene SMART (genes and the Skeletal Muscle Adaptive Response to Training) Study aims to identify genetic variants
that predict the response to both a single session of High-Intensity Interval Exercise (HIIE) and to four weeks of High-
Intensity Interval Training (HIIT). While the training and testing centre is located at Victoria University, Melbourne, three
other centres have been launched at Bond University, Queensland University of Technology, Australia, and the
University of Brighton, UK. Currently 39 participants have already completed the study and the overall aim is to recruit
200 moderately-trained, healthy Caucasians participants (all males 18–45 y, BMI < 30). Participants will undergo exercise
testing and exercise training by an identical exercise program. Dietary habits will be assessed by questionnaire and
dietitian consultation. Activity history is assessed by questionnaire and current activity level is assessed by an activity
monitor. Skeletal muscle biopsies and blood samples will be collected before, immediately after and 3 h post HIIE, with
the fourth resting biopsy and blood sample taken after four weeks of supervised HIIT (3 training sessions per week).
Each session consists of eight to fourteen 2-min intervals performed at the pre-training lactate threshold (LT) power
plus 40 to 70% of the difference between pre-training lactate threshold (LT) and peak aerobic power (Wpeak). A number
of muscle and blood analyses will be performed, including (but not limited to) genotyping, mitochondrial respiration,
transcriptomics, protein expression analyses, and enzyme activity. The participants serve as their own controls. Even
though the gene SMART study is tightly controlled, our preliminary findings still indicate considerable individual
variability in both performance (in-vivo) and muscle (in-situ) adaptations to similar training. More participants are
required to allow us to better investigate potential underlying genetic and molecular mechanisms responsible for this
individual variability.
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Background
Individual variability in the response to similar exercise
training
Despite the proven health and performance benefits of
exercise training, it is clear there is considerable individ-
ual variability in the response to similar exercise training
[1–4]. This means some people are ‘low/medium re-
sponders’ (with limited improvements following exercise
training), while others are ‘high-responders’ [5]. A high
inter-individual variability in the response to similar
physical exercise is consistently reported in training
studies, even within homogenous groups of previously
untrained subjects and after fully compliant and super-
vised training [6, 7]. For example, in the pioneering
Health, Risk factors, Training and Genetics (HERITAGE)
study, changes in aerobic capacity were observed to vary
markedly in a group of sedentary adults after similar
exercise training [1]. Recently, we have also shown large
individual variability for changes in skeletal muscle
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mitochondrial function (respiration) in response to high-
intensity exercise training [8]. Identifying and under-
standing the molecular pathways contributing to the
individual response to exercise training is challenging,
but has exciting potential implications for “personal
medicine” and the future development of individualised
exercise training programs [9]. While exercise training is
an important non-pharmacological intervention to im-
prove health, and to reduce the risk for many chronic
diseases, it is anticipated that personalising training
using not only environmental factors (e.g., specific diet
and training etc.), but also biological markers (i.e., gen-
omics, transcriptomics, proteomics, and metabolomics)
will have important health and economic ramifications
by ensuring that specific exercise interventions are pre-
scribed so as to attain the greatest benefit.
Genetic basis of individual response to exercise training
The underlying aetiology for this large variation in the
training response remains to be discovered. However,
different lines of research indicate there is a strong gen-
etic component. Studies in the 1980s, involving twins
and siblings, have demonstrated that variance in max-
imal oxygen uptake (V

O2max ) and the lactate threshold
(LT) was smaller within monozygotic than within dizyg-
otic twins and brothers of the same sibship [10, 11]. Fur-
thermore, even though there were large individual
differences in response to a 3-month exercise interven-
tion with controlled energy intake, participants with the
same genotype (i.e. monozygotic twins) were more alike
in responses than participants with different genotypes
(between different pairs of monozygotic twins), par-
ticularly for changes in body fat, body weight, and
abdominal visceral fat [12]. Adaptations in V

O2max and
endurance performance after 15 weeks of exercise train-
ing were also more similar (>4.6 and >9.7 times more
similar respectively) within the monozygotic twin pair
than between different pairs monozygotic twins [11].
Similarly, changes in muscle enzyme activities after
training, such as malate dehydrogenase and oxoglutarate
dehydrogenase, were partially genetically dependent,
with more similar adaptations within the monozygotic
twin pairs than between different pairs of twins during
the last 8 weeks of training [11].
The most comprehensive data, thus far, concerning the
genetic contribution of the responsiveness to a standardised
exercise training program, arises from the HERITAGE
study with the calculated heritability of training adaptations
in V

O2max reported to range from 45% to 50% [13]. To fur-
ther explore the potential underlying genetic component,
the candidate gene approach was first employed. More than
100 candidate gene variants have subsequently been re-
ported to be associated with the response to exercise
training [14–16]; however, most of these variant have not
been replicated in other studies and it is likely that some of
them are false positives and not truly associated with train-
ing responses. Developments in microarray-based, high-
throughput technologies have allowed researchers to move
beyond the candidate gene approach to unbiased analysis
of thousands of common Single-Nucleotide Polymorphisms
(SNPs) simultaneously [13]. However, to date, only a few
genome-wide association (GWA) trainability studies have
been published, all using V

O2max as a response trait, and
all have arisen from the HERITAGE cohort [16–18].
In the first report, microarray was used to identify genes
associated with the V

O2max training response, based on
global skeletal muscle gene expression profiling and DNA
markers of 24 participants [17]. A total of 29 transcripts
were strongly associated with the gains in V

O2max, with 11
SNPs explaining approximately 23% of the variance in the
V

O2max training response [17]. The second GWA report,
with 473 participants from the HERITAGE study, analysed
more than 320,000 SNPs [16]. A total of 39 different SNPs
were associated with the V

O2max training response, with
the strongest evidence of association observed in the first
intron of the acyl-coA synthetase longchain family member
1 (ACSL1) gene [16]. Nine SNPs each explained at least 2%
of the variance, while 7 contributed between 1 and 2% each
[16]. This study showed that 21 SNPs accounted for 49%
of the variance in V

O2max trainability, a value comparable
to the heritability estimate of 47% in V

O2max trainability
reported previously in the HERITAGE study [1]. The third
study used a system biology-based approach to predict
V

O2max training response, through considering multiple
DNA sequence variants [18]. The study retested the 21
SNPs previously published, by mapping nearly 2.5 million
SNPs strictly based on their location within a 20-kb win-
dow on either side of a gene. Through this it has been
confirmed the SNP in the ACSL1 gene (rs6552828) con-
tributed to about 6% of the training response of V

O2max ,
as well as SNPs in the other three genes CAMTA1,
BIRC7, and CD44 [18]. Five genes did not overlap, and 12
of the 21 genes could not be compared because the genes
were mapped more than 20 kb away from the SNPs [18].
Gaps in literature
Despite advances in the field of Exercise Genomics, several
limitations in current training studies exist. First, the par-
ticipants in the majority of training-studies are not rigor-
ously selected and are not tightly-controlled (i.e., large
differences in base-line physical activity-level, nutrition sta-
tus, sex, and ethnicity). Second, the majority of training
studies into the effect of genes on exercise have not pro-
vided any proposed cellular or molecular mechanisms to
explain the individual variation in the training response.
The reason is that these studies are mainly based on
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physiological phenotypes, such as V

O2max , and have not
collected muscle and/or blood samples pre- and post-
training. Lastly, many of the training studies have a sample
size of between 10 to 30 participants, with a potential large
variation in the participant’s base-line physical activity level,
and hence relatively small effects of a target gene. Conse-
quently, the Genomic, Transcriptomic, Proteomic, and
Metabolomic (OMICS) profile of either low or high re-
sponders to exercise training remains poorly characterised.
Significance and aim of the gene SMART (genes and the
skeletal muscle adaptive response to training) study
The gene SMART study, a part of the recently estab-
lished ATHLOM Consortium [19], is a multi-centre
(Victoria University, Australia; Bond University, Australia;
Queensland University of Technology, Australian; and
The University of Brighton, UK), tightly-controlled,
exercise training study (please see “Study Design and
Sampling” section). The overarching aim of this multi-
centre study is to use a system biology approach (with
current state-of-the-art technology) to identify the
genomic (gene variants), transcriptomic (gene expression
profile), metabolomics (enzyme activities), and proteomic
(proteins abundance) factors predicting the response to
both a single session of high-intensity interval exercise
(HIIE) and to 4 weeks of high-intensity interval training
(HIIT), in a relatively-large group (N = 200) of
participants. It is anticipated that this research will provide
significant new information on the biological basis of
adaptation to exercise training, and may also have
implications for talent identification and the training of
elite athletes.
Study design and sampling
Study overview
A study flow chart is shown in Fig. 1. Briefly, potential
participants will first express their interest online, and
will then be contacted by a research coordinator. If the
potential participant satisfies all of the inclusion criteria
(please see ‘Participants’ section for the study criteria),
they will be scheduled to meet with one of the research
team members to receive an in-depth explanation of the
study design, as well as an explanation on the benefits
Fig. 1 Study flow chart with timeline
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and the potential risks of participating in this study. At
that time, they will be asked to carefully read and
complete a consent form and risk assessment question-
naires. The participant will then be given an activity
monitor and a data sheet to monitor their physical
activity for 1 week. During this week they will also be
scheduled to meet a dietitian, who is a member of our
team, and who will provide nutritional consultation for
the length of the study. The participants will commence
their base-line (pre-training) exercise tests the following
week, which will take 2 weeks to complete (Fig. 2). Fol-
lowing the final base-line testing, and 48 h prior to the
pre-training resting muscle biopsy, participants will be
given a 48-h standardised diet. Two days after the first
training session (which includes the resting biopsy as
well as 2 post-exercise biopsies) the participants will
commence the remaining 11 sessions of HIIT. The par-
ticipant will repeat the 48-h standardised diet before the
post-training resting muscle biopsy. Following the post-
training biopsy, the participant will be allowed to recover
for 48–72 h and then repeat the pre-training exercise
testing to evaluate their training response. Finally, to
maximise the participant’s benefits, the exercise training
and testing results will be explained to the participant by
a senior member of the research team.
Participants
Two hundred moderately-trained (V

O2peak 35–60 mL·min
−1·kg−1) men, aged 18 to 45 y, from the student and staff
populations of the participating universities and the local
communities, will be recruited for the study. For the pur-
pose of genotyping, and to avoid genetic skew, we will en-
sure that all participants are unrelated Caucasians for ≥3
generations using a written questionnaire and ancestry
genomic markers. Participants will have a Body Mass Index
(BMI) between 20 and 30 kg·m−2 and a body fat percent-
age < 25% [20, 21].
Recruitment of eligible volunteers is based on exten-
sive publicity and a combination of campus advertise-
ments, newspaper advertisements, radio and television
exposures, and community contacts. A university web-
site has also been developed at Victoria University
(www.vu.edu.au/speed-gene). A research coordinator has
been hired to deal with volunteer communications, and
testing & training schedules. Potential participants will
initially be screened on the phone, followed by a more
extensive screening done at the research centre. The
study has been approved by the human ethics committee
of each participating institution and written informed
consent will be obtained from each participant.
A detailed medical history will be assessed by
questionnaire. Participants will be excluded from the
study if they have a past history of the following medical
conditions: definite or possible coronary heart disease,
significant chronic or recurrent respiratory condition,
significant neuromuscular, major musculoskeletal prob-
lems interfering with ability to cycle, uncontrolled endo-
crine and metabolic disorders or diabetes requiring
insulin and other therapies.
Sample size
The proposed sample size (200 participants) is designed
to yield enough power for hypothesis testing and to ob-
tain reliable results. The complexity of this study makes
it impossible for a single centre to complete all the
analysis, which is why three out of four centres (Bond
University, Australia; University of Brighton, UK and
Queensland University of Technology, Australia) will
serve as an ‘OMIC’ centre to perform genomic, tran-
scriptomic, and metabolomic analyses. Similar to the
HERITAGE study [22], we have included multiple
criteria for inclusion and exclusion. However, we are
well aware that heterogeneity among the four centres
can be a potential limitation. Before we combine the
data together, we will first test the within-centre and
among-centre differences.
Experimental overview
Pre-training physical activity monitoring
To control for potential differences in habitual physical
activity between participants, 1 week prior to commencing
Fig. 2 Overview of exercise testing and training. Fam, familiarization; 20 km-TT, 20 km cycle time trial; GXT, graded exercise test to exhaustion;
HIIE, high-intensity interval exercise
The Author(s) BMC Genomics 2017, 18(Suppl 8):821 Page 18 of 131
the study, we will monitor the participant’s activity level
for seven consecutive days. Monitoring participants’
activity level will be performed using an ActiGraph
GT3X+ device (ActiGraph LLC, Fort Walton Beach, FL,
USA). The GT3X+ activity monitor provides objective
measurements of human activity, and has been used in
many research [23, 24] and clinical applications [25, 26].
The device includes a micro-electro-mechanical system
based tri-axis accelerometer sensor that provides mea-
sures of acceleration in three axes, with a composite meas-
ure called the vector magnitude (VM = √(×2 + y2 + z2)).
The accelerometer has ±6 g range with a sampling rate
ranging from 30 Hz to 100 Hz (user selectable) storing the
raw, non-filtered/accumulated data, in the units of gravity.
The device can sample continuously for between 24 and
32 days depending on the selected sampling frequency.
The ActiGraph GT3X+ device can be threaded onto
an elastic belt and worn either over or under clothing,
whichever is most comfortable for the participant. The
device is positioned snugly enough against the body so
that it cannot flop around. The device is worn with the
elastic belt fastened around the waist over the right hip
bone all day while the participant is awake. The only
times the device can be removed is when the participant
goes to bed at night, or if the unit would become com-
pletely wet (e.g., swimming and showering). A daily diary
will assist in monitoring when the device is being re-
moved, and to account for any water-based activities.
The acceleration data will be downloaded from the de-
vice and processed over a user-specified time sampling
interval. Energy expenditure and activity intensity will be
calculated using algorithms that have been derived by in-
dependent researchers from around the world [27, 28].
Cutpoints will be used according to Freedson et al. [27],
to calculate METs (metabolic rate) and level of activity.
METs measure will be incorporated as a covariate, and
level of activity will be used to categorise participants
into groups; Light, Moderate, Vigorous, and Very
Vigorous. The collected data will be incorporated into
the data analysis, and used as a covariate in subsequent
statistical analyses.
Nutrition consultation
Each participant will be provided with individualised, pre-
packaged meals for the 48 h prior to the first and last rest-
ing muscle biopsies. The energy content of the provided
meals will be calculated using the Mifflin St-Jeor equation
and each participant’s body mass (BM), height and age
[29]. The Foodworks (Xyris) nutritional data base will be
used to determine the nutritional components of the
packaged meals and to ensure all nutritional requirements
will be met with the diet. The content of the diets are
constructed based on the current National Health and
Medical Research Council (NHMRC) guidelines. To
ensure adequate access to carbohydrate energy stores dur-
ing each training session, participants will be asked to
consume a pre-packaged training meal of high glucose
food items (1.5 g·kg−1 BM) 2 h prior to the commence-
ment of each training and testing session, according to
suggestions from the Australian Institute of Sport (AIS)
[30]. Participants will be provided with a post-training and
post-testing meal consisting of protein (0.3 g·kg−1 BM)
and carbohydrates (0.3 g·kg−1 BM) [31]. Participants will
also be asked to refrain from alcohol and caffeine during
the dietary control period, which is 48 h prior to each rest-
ing biopsy. Outside of the dietary-control period they will
continue with their normal exercise and dietary habits.
Performance tests
Prior to the start of the High-Intensity Interval Training
(HIIT) phase, all participants will complete familiarisation
and baseline testing (see Fig. 2). All visits will be separated
by a minimum of 48 h. In addition, participants will be re-
quired to refrain from exercise, alcohol and caffeine con-
sumption for 24 h before all tests. The familiarisation and
baseline testing will consist of the following:
1. 20 km cycle Time Trial (20 km - TT) - During the
first (familiarisation) and third visits (baseline test)
participants will perform a 20 km - TT on a
Velotron® cycle eogometer (RacerMate Inc. Seattle,
WA, USA). Participants will complete a warm-up
consisting of 5 min of cycling at 60 W. Following a
2-min rest, participants will then be required to
complete the 20 km - TT in the quickest possible
time. During the time trial, power output measures
and time will be concealed from the participants.
However, participants will be permitted to monitor
their progress through completed distance and
will be provided with verbal encouragement during
the test.
2. Graded exercise test to exhaustion (GXT) - During
the second (familiarisation), fourth, and fifth visits
participants will undertake a GXT, for baseline
determination of the lactate threshold (LT) and peak
aerobic power (Wpeak). This test will be performed
on an electronically-braked cycle-ergometer
(Lode-excalibur sport, Groningen, the Netherlands)
and will consist of 4-min stages separated by 30-s
rest periods until exhaustion. The test will start at
60, 90 or 120 W (depending on the participant’s
20 km - TT results) and will be increased by 30 W
in each subsequent stage. Capillary blood samples
will be taken at rest, after each completed stage, and
immediately following exhaustion, and will be
analysed by a YSI 2300 STAT Plus system
(Yellow Springs, Ohio, USA). During the GXT the
LT will be calculated by the modified DMAX
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method, which is determined by the point on the
polynomial regression curve that yields the
maximum perpendicular distance to the straight line
connecting the first increase in lactate concentration
above resting value and the final lactate point
[32, 33]. The average of the two GXT tests will be
used to individualise exercise intensities, if the
difference is no more than 5%, otherwise the highest
value will be used.
3. V

O2peak test - After 5 min rest following the GXT,
peak oxygen consumption (V

O2peak) will be
measured using a calibrated Quark CPET metabolic
system (COSMED, Rome, Italy). Briefly, participants
will wear the Cosmed face mask and we will collect
VO2 at stationary for 2 min, while exercising for
3 min at the intensity of the first stage of GXT
(60, 90 or 120 W), and during exercise to exhaustion
at 105% of Wpeak measured during the previous
GXT. V

O2peak will be considered the highest value
in 1 min obtained during the test. Data from
previous studies have shown the V

O2peak measured
this way is not different from that derived from a
ramp test [34]. The HIIT phase will commence
48–72 h after the last baseline exercise test.
Muscle biopsies
Muscle biopsies will be performed on the vastus lateralis
muscle of the participants’ dominant leg. Following in-
jection of a local anaesthetic (5 mL, 1% Xylocaine), inci-
sions will be made and the biopsy needle will be
inserted. Muscle samples will be collected with manual
suction applied [35]. Following collection, the samples
(50–200 mg) will be immediately blotted on filter paper
to remove excess blood, with a small portion (10–
15 mg) immediately processed for the determination of
mitochondrial respiration [36]; about 10 mg will also be
embedded in Tissue-Tek ® O.C.T. Compound for muscle
structure analysis, with the remaining muscle snap fro-
zen in liquid nitrogen before being stored at −80 °C for
subsequent analyses.
Blood sampling
Venous blood samples will be collected through
venipuncture or cannulation, immediately after each
muscle biopsy. Five mL venous blood will be collected
with BD Vacutainer EDTA blood collection tubes
(Becton, Dickinson and Company, USA), inverted 6–10
times, centrifuged at 3500 rpm for 10 min at 4 °C, and
the resulted supernatant plasma samples will be col-
lected and aliquoted carefully into Eppendorf tubes. The
residual blood sample will be saved for DNA extraction.
Five mL blood will be collected with BD Vacutainer SST
tubes (Becton, Dickinson and Company, USA), left at
room temperature for 15 min, centrifuged at 3500 rpm
for 10 min at 4 °C, and the resulted supernatant serum
samples will be collected and aliquoted carefully into
Eppendorf tubes. Three mL blood will be stored in
Tempus® Blood RNA tubes (Applied Biosystems, USA)
and shaken vigorously for 30 s, and then stored at 20 °C
for RNA extraction.
Acute high intensity interval exercise (HIIE) phase
Following the pre-training baseline muscle biopsy and
venous blood sampling, participants will perform a
single session of HIIE on an electronically-braked cycle
ergometer (Velotron®, Racer Mate Inc., Seattle, USA). The
session will consist of eight 2-min intervals performed be-
tween the individually-determined pre-training LT power
and Wpeak (LT + 40% (Wpeak - LT)), and interspersed
with 1-min recovery periods (work-to-rest ratio of 2:1).
Muscle biopsies and venous blood samples will be taken
immediately after and 3 h post the HIIE to measure muscle
and blood biomarkers, including (but not limited to)
mitochondrial respiration, transcriptome, protein expres-
sion analyses, and enzyme activity (Fig. 2).
HIIT phase
Participants will be required to train 3 times per week
for 4 weeks (12 sessions) (Fig. 2). All training sessions
will be completed on an electronically-braked cycle
ergometer (Velotron®, Racer Mate Inc., Seattle, USA),
and will be preceded by a 5-min warm up at 60 W. Each
session will consist of six to fourteen 2-min intervals
performed at intensities ranging from the power at their
individually-determined LT power plus 40 to 70% of
difference (Δ) between their individually-determined
Wpeak (derived from the baseline GXT test results) and
Table 1 Details of the 4 wk. high-intensity interval training
(HIIT) program
Session Intensity (LT + % ofΔ) Number of intervals
1 LT + 40%Δ 8
2 LT + 40%Δ 9
3 LT + 40%Δ 10
4 LT + 50%Δ 10
5 LT + 50%Δ 12
6 LT + 50%Δ 11
7 LT + 60%Δ 11
8 LT + 60%Δ 12
9 LT + 60%Δ 14
10 LT + 70%Δ 11
11 LT + 70%Δ 9
12 LT + 70%Δ 6
Δ = peak aerobic power (Wpeak) – power at lactate threshold (LT); 1 interval
consists of 2 min of exercise followed by 1 min of rest. There will also be a
5-min warm-up before each training session and a 5-min cool-down following
each training session
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the power at the LT (LT + 40–70% Δ), and interspersed
with 1-min recovery periods at a power of 60 W (work-
to-rest ratio of 2:1). In order to maintain progression,
there will be a different numbers of intervals per session
(as shown in Table 1).
Post-training sampling and tests
At the completion of training, participants will report to
the lab four times and the visits will be separated by a
minimum of 48 h. During their first visit, a resting
muscle biopsy and venous blood sample will be collected
(Fig. 2). Before the biopsy, a 48-h control diet will again
be given to the participants (as described in the
‘nutrition consultation’ section). At the second and
fourth visits, post-training GXTs and V

O2peak tests will
take place at the same time of day as the pre-training to
assess changes in V

O2peak and LT (Fig. 1). The average
of the two GXT tests will be used to determine the influ-
ence of training on common physiological determinants
of endurance performance if the difference is less than
5%. If the difference is more than 5%, the highest value
will be used. During the third visit participants will per-
form a post-training 20 km-TT (Fig. 2).
Data entry and management
A distributed data entry system has been developed for
the gene SMART study using Microsoft software at the
Victoria University (R-Drive). Each university will enter
the data on its own computer and send it to the data
coordinating centre at Victoria University. Victoria
University registers collections/data available for reuse in
Research Data Australia, the national ANDS registry -
http://researchdata.ands.org.au/victoria-university. Victoria
University also hosts data.vu.edu.au - an institutional re-
pository that can be used to make appropriate digital col-
lections available for reuse. We will ensure the responsible
management of data, materials and records during the
project, and that after the project data is retained in a dur-
able format and can be appropriately accessed. Victoria
University provides enterprise-grade, secure, storage and
backup for safe storage during research and for long term
retention. Physical records and material are retained within
the university colleges. To mitigate the risks associated
with genetic research, all data will be stored anonymously;
we will not release gene data to participants, nor release
gene data to any third parties. DNA samples will be kept
for a minimum of 5 years post publication and will
then be discarded.
Muscle and blood analysis
Genotyping
Genomic DNA will be extracted from residual blood sam-
ples from BD Vacutainer EDTA tubes using the MagSep
Blood gDNA kit (0030 451.00, Eppendorf, Hamburg,
Germany) or GeneJET Genomic Whole Blood DNA Puri-
fication Kit (#K0781 Thermo Scientific, MA, USA). Can-
didate gene variants will be determined using the TaqMan
SNP assay (Applied Biosystems, Thermo Fisher Scientific,
CA, USA) by QuantStudio 7 Flex (Applied Biosystems,
Thermo Fisher Scientific, CA, USA). Genotyping will be
replicated in another independent institute, as previously
described [37, 38], to validate the results. A Genome-
Wide Association Study (GWAS) approach will also be
performed on collected samples (Illumina OmniExpress
array chips). Genotyping of genomic DNA will be per-
formed using Human Infinium OmniExpress-24 v1.2
BeadChip, containing a maximally informative set of more
than 720,000 tag SNPs. Tag SNPs content is optimized
from all 3 HapMap phases. The ~720,000 SNP content
also includes non-synonymous SNPs, the MHC region,
mitochondrial and Y chromosome SNPs. In addition to
these tag SNPs, approx 14,000 highly polymorphic CNV
regions are specifically targeted, including segmental
duplications and regions in the unSNPable genome. The
Illumina® Infinium™ II Assay involves an extremely high
volume genotype multiplex reaction using a single bead
type and dual colour channel approach. This reaction
allows hundreds of thousands of SNPs to be genotyped
for a single DNA sample. The Assay accomplishes this
high volume multiplex reaction by combining whole gen-
ome amplification of a 200 ng quantity of genomic DNA
starting material with direct, array-based capture and en-
zymatic scoring of the SNP loci. Locus discrimination is
provided by a combination of sequence-specific
hybridization capture and array-based, single-base primer
extensions. The Assay will be assessed using the Genotyp-
ing Module of Illumina’s Beadstudio software (ver. 2.0).
The dependent variables of the proposed study will be
analysed as quantitative traits and where necessary will
be normalised by transformation as previously deter-
mined. In addition to considering the cohort phenotypes
individually we will perform multivariate analyses of
phenotypes. For multiple traits that exhibit a multivari-
ate approach we will perform principal components fac-
tor analysis (PCFA) to convert phenotypes into a linear
combination of independent variables (component traits)
that explain a large portion of the overall trait variance.
In addition, we will weight the phenotypes included in
the PCFA based on heritability estimates calculated in
the PLINK program [39]. We will follow-up single gene
associations by performing multi-gene signature analysis
to identify core genetic pathways involved.
Mitochondrial genome will be sequenced using a Next
Generation Sequencing with the Ion Proton Platform
(Life Technologies, Thermo Scientific) library sequen-
cing method. Briefly, mitochondrial DNA will be
extracted, enriched by long range PCR to produce
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overlapping fragments covering the entire mitochondrial
genome and purified prior to library preparation and
NGS. Raw sequence reads will be aligned to the revised
Cambridge Reference Sequence (rCRS) using SAMTOOLs
to produce Binary Alignment (BAM) files. A custom script
will be used to call variants relative to the reference gen-
ome. Variants which pass quality control will then be ana-
lysed using a logistic regression model in PLINK [39].
Variants with a MAF of <0.01 will be excluded from the
final regression model to avoid skewing of results.
Common SNPs will be analysed separately using a Fisher’s
exact test in Plink v1.09. The regression test will factor in
for the covariates age, gender and kinship with RNAfold
used to predict secondary structural changes to 12S rRNA.
A minimum sequencing depth of 16,000 x coverage will
allow us to examine heteroplasmic variants, present in a
proportion of sequencing reads.
Muscle analysis
We will use high throughput muscle analysis for the dis-
covery phase and low throughput for verification, as out-
lined below.
Mitochondrial respiration
Immediately after each resting biopsy, muscle fibres will
be separated gently on ice under a binocular microscope
in BIOPS solution (2.77 mM CaK2EGTA, 7.23 mM
K2EGTA, 5.77 mM Na2ATP, 6.56 mM MgCl26•H2O,
20 mM Taurine, 15 mM Na2Phosphocreatine, 20 mM
Imidazole, 0.5 mM Dithiothreitol, and 50 mM MES at
PH7.1), and permeabilised in the same solution with
50 μg/ml of saponin (Sigma-Aldrich, St Louis, USA) for
30 min. This will be followed by rinsing the muscle fibres
for 3 × 7 min in mitochondrial respiration medium on ice
(0.5 mM EGTA, 3 mM MgCl2•6H2O, 60 mM K-
lactobionat, 20 mM Taurine, 10 mM KH2PO4, 20 mM
Hepes, 110 mM sucrose, and 1 g•L−1 bovine serum albu-
min at pH 7.1). Experiments will be performed on washed
muscle fibres under continuous stirring using an
oxygraph-2 k respirometer (Oroboros Instruments,
Austria), containing 2 mL of mitochondrial respiration
medium with additional substrates at 37 °C. The following
substrates will be added (final concentration): malate
(2 mM) and pyruvate (5 mM) to support electron entry to
complex I (CI); MgCl2 (3 mM) and ADP (5 mM) to meas-
ure Oxidative phosphorylation (OXPHOS) capacity; Suc-
cinate (10 mM) to stimulate CI + II-linked respiration and
providing convergent electron input into the Q-junction
simultaneously (CI + IIP) [17]. A maximal respiratory cap-
acity is reached when these substrates are present in the
respirometer chamber [17]. Cytochrome c (10 μM) will be
used to test the integrity of the outer mitochondrial mem-
brane [2]. Electron transfer system capacity (ETS with
CI + II-linked substrates, CI + IIE) will be tested by
titrating p-trifluoromethoxyphenylhydrazone (FCCP)
(steps of 0.5 μM) until maximal noncoupled respiration is
reached. Rotenone (0.5 μM) will then be added to block
the activity of complex I so that electrons can only enter
through complex II (CII). Antimycin (3.75 μM) will be
added to block the activity of complex III and to measure
the non-mitochondrial respiration. Different ratios (sub-
strate and coupling control ratios) will be calculated from
the different titration steps obtained from the protocol
used [17].
Enzyme assay
Complete enzyme extractions from small pieces of frozen
tissues will be done in an ice-cold buffer (50 mg•mL−1;
containing (in mM): Hepes 5 (pH 8.7), EGTA 1, DTT 1,
and 0.1% Triton X-100) using a TissueLyser II (Qiagen,
Hilden, Germany). Protein concentration is assessed using
the bicinchoninic acid assay. Total activities of cyto-
chrome oxidase (COX), citrate synthase (CS), creatine
kinase (CK), adenylate kinase (AK), β-hydroxyacyl-CoA
dehydrogenase (HADHA) and lactate dehydrogenase
(LDH) will be assayed (30 °C, pH 7.5) using standard spec-
trophotometric assays.
Activities will be represented as μmol·min−1·(g protein)−1
or international units (IU). CK isoenzymes will be
separated using agarose (1%) gel electrophoresis per-
formed at 250 V for 90 min. Individual isoenzymes
will be resolved by incubation of the gels with a
coupled enzyme system [40].
Western blots
Approximately 10mg of frozen muscle samples will be
homogenised in ice-cold RadioImmunoPrecipitation Assay
(RIPA) lysis buffer (50 mM Tris·HCl, pH 7.4, 150 mM
NaCl, 0.5% Sodium Deoxycholate, 1% Triton X-100, 0.1%
SDS, 1 mM EDTA with protease/phosphatase inhibitors,
1 mM PMSF, 1 g/mL Aprotinin, 1 g/ml Leupeptin, 1 mM
Benzamedine, 1 mM Na3VO4, 5 mM Na Pyrophosphate,
1 mM DTT and 1 mM NaF) using a TissueLyser II
(Qiagen, Hilden, Germany) for 2 × 1 min at 30 Hz, and ro-
tated for 1 h at 4 °C. Muscle lysates will be stored at −80 °C
until further analysis. Total protein content of muscle ly-
sates will be determined using the bicinchoninic acid assay.
Protein extracts will be loaded on sodium dodecyl sul-
fate polyacrylamide gels, separated for 120 min at 100 V
and subsequently transferred to PolyVinyl DiFluoride
(PVDF) membranes (Bio-Rad Laboratories, Hercules,
USA) using a Bio-Rad blot system for 100 min at 100 V.
Thereafter, blots will be blocked for 60 min in 5% milk in
tris-buffered saline (TBS) and washed with TBS plus 0.1%
Tween at room temperature, followed by incubation with
different primary antibodies (including but are not limited
to, Citrate Synthase, Cytochrome C, p53, PGC1α, PPARα,
total oxphos), UCP3 and etc) overnight at 4 °C. After
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washing, the membranes will be incubated with the
appropriate secondary antibodies for 60 min at room
temperature and revealed using a chemiluminescent sub-
strate (Bio-Rad Laboratories, Hercules, USA). Light emis-
sion is recorded using ChemiDoc™ MP System (Bio-Rad
Laboratories, Hercules, USA) and quantified by image-
analysis software (Image Lab, Bio-Rad). Protein content
will be normalised to total protein analysis via TGX stain-
free gel (Bio-Rad Laboratories, Hercules, USA) [41].
RNA extraction, gene expression and whole transcriptome
analyses
Total RNA will be extracted from approximately 15 mg
of frozen muscle. Cellular membranes will be dissociated
in TRIzol® Reagent (Invitrogen, Melbourne, Australia)
through TissueLyser II (Qiagen, Hilden, Germany) for
2 × 1 min at 30 Hz. The homogenate will be centrifuged
(13,000 RPM for 15 min) and the RNA containing
supernatant removed. The homogenate will then be
combined with chloroform (Sigma-Aldrich, St Louis,
USA) and total tissue RNA is then extracted using the
TRIzol protocol in accordance with the manufacturer’s
instructions, with the exception of RNA precipitation
which will be conducted for a minimum of 2 h at −20 °C
in the presence of 10 μL of 5 M sodium chloride. RNA
concentration will be quantified spectrophotometrically at
260 nm and purity will be checked using the ratio of its
absorbance at 260 and 280 nm using a BioSpectrometer
(Eppendorf, Hamburg, Germany). First strand cDNA is
then generated from 1 μg of template RNA using the
commercially available iScript™ cDNA synthesis kit (Bio-
Rad Laboratories, Hercules, USA) using random hexamers
and oligo dTs according to the protocol provided with
the iScipt cDNA synthesis kit (Bio-Rad Laboratories,
Hercules, USA). cDNA will be stored at −20 °C for subse-
quent analysis. All samples and reverse transcriptase (RT)
negative controls will be run together to prevent technical
variation. Forward and reverse primers for the target and
housekeeping genes will be designed based on NCBI
RefSeq using NCBI Primer-BLAST (www.ncbi.nlm.nih.
gov/BLAST/). Primers will include but are not limited to,
18 s, B2M, Cyclophilin, GAPDH, TBP, Citrate Synthase,
Cytochrome C, p53, PDK4, PGC1α, PPARα, and etc.
Specificity of the amplified product will be confirmed by
melting point dissociation curves generated by the PCR
instrument. The mRNA expression of target and house-
keeping genes will be quantified by quantitative real-time
RT-PCR (QuantStudio™ 7 Flex Real-Time PCR System
(Life Technologies, Thermo Fisher Scientific, Wilmington,
DE, USA), using a 5 μL PCR reaction volume and SYBR®
Green chemistry (iTaqTM Universal SYBR® Green
Supermix, Bio-Rad, Hercules, CA). All samples will be run
in duplicate simultaneously with template free controls,
using an automated pipetting system (epMotion 5073,
Eppendorf, Hamburg, Germany). The following PCR cyc-
ling patterns will be used: initial denaturation at 95 °C for
3 min, 40 cycles of 95 °C for 15 s and 60 °C for 60 s.
Blood analysis
Cytokines and other blood markers of trainability
Plasma and serum samples will be analysed to determine
cytokines, fatty acids, glucose, insulin and other health-
related blood markers. Cytokines will be analysed using
Bio-Plex Pro™ Human Cytokine, Chemokine, and Growth
Factor Assays (Bio-Rad, California, USA). Glucose will be
analysed via a YSI 2300 STAT Plus system (Yellow
Springs, Ohio, USA). Insulin will be analysed by using hu-
man insulin specific RIA lit (Millipore, Missouri, USA).
RNA extraction and whole transcriptome analysis
Total RNA will be isolated from the whole blood
collected in the Tempus tubes according to the manu-
facturer’s instruction (Tempus™ Spin RNA Isolation Kit,
Life Technologies, Carlsbad, CA, USA). The purified
total RNA will be eluted in 90 μL elution buffer and
stored in three aliquots at −80 °C until further analysis.
Quality and quantity of isolated RNA will be assessed
using the Nandrop Technologies Nanodrop® ND-2000
Spectrophotometer (Wilmington, DE, USA). RNA integ-
rity will be evaluated using the Agilent 2100 Bioanalyzer
(Agilent technologies, Santa Clara, USA).
The purified total RNA will be amplified and labelled
using the GeneChip® WT PLUS Reagent Kit (Affymetrix,
Santa Clara, CA, USA). The labelled samples will then
be randomly hybridized to the GeneChip® Human
Transcriptome Array 2.0 (Affymetrix, Santa Clara, CA,
USA) according to the manufacturer’s recommendations.
The GeneChip arrays will be incubated in the GeneChip®
Hybridization Oven 645, washed and stained on the
GeneChip® Fluidics Station 450 and scanned using the
GeneChip® Scanner 3000 7G (Affymetrix, Santa Clara,
CA, USA).
Data analysis
Appropriate statistical tests, with multiple comparisons,
will be used for data analysis, using both the SPSS and
the R packages. A p value will be considered as sig-
nificant depending on the statistical test and number of
tests. Multiple testing corrections will be applied
accordingly.
For transcriptome data obtained from the Affymetrix
GeneChip, Affymetrix® Expression Console™ (version
1.4.1) will be used to perform initial data QC, visualisa-
tion, normalisation and summarisation. Bioconductor
packages - “oligo” [42] will be used to analyze Affymatrix
GeneChip. CEL files at the probe-level; “rma()” function
for background correcting, normalizing and calculating
expression, and creating the expression dataset to be
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used for following analysis; and the “sva” (surrogate
variable analysis) package [43] in conjunction with the
“f.pvalue()” function, “limma” package [44] and “ComBat()”
function for estimating and adjusting for surrogate vari-
ables, known batches and other artefacts. “pcaGoPromo-
ter” package [45] will then be used to examine overall data
structure after the batch effect removal. Finally, “limma”
functions will be used to perform the usual differential ex-
pression analysis based on the adjusted data. FDR < 0.05
and a 2-fold change will be considered significant.
Progress to date
Planning and the development of exercise testing, and ex-
ercise trainings began in 2014. Following that, recruitment
and data collection was initiated at Victoria University,
with 64 participants completing the HIIE and 39 partici-
pants completing the HIIT to date. Muscle samples for
gene expression and protein abundance are being analysed
at Victoria University, while key blood samples are being
analysed at the Brighton University centre for blood tran-
scriptome analyses. We anticipate the recruitment of 200
participants across centres by the end of 2020.
Results and discussion
Figures 3 and 4 show the individual changes of physio-
logical and performance-related measurements after 4
week HIIT (n = 39). As shown in Fig. 3a, the average
improvement in V

O2peak is 3.85% (or 128.5 mL ∙ min
−1, p
< 0.001), lower than what was reported in the HERITAGE
study (~13% or 393 mL ∙ min−1). However, the duration of
the HERITAGE study was 20 week (vesus 4 week in the
current study), and they recruited non-active or sedentary
participants whereas we recruited moderately-trained par-
ticipants. A recent meta-analysis reported that training-
induced gains in the V

O2peak are generally higher with
longer durations and in those with lower baseline V

O2peak
[46] (baseline V

O2peak in the gene SMART = 3871.82 mL
∙ min−1 vs. V

O2max of 3022.36 mL ∙ min
−1 in the male sub-
jects of the HERITAGE study [1]). Furthermore, we have
previously observed a similar, small percentage increase in
V

O2peak in moderately-trained participants undergoing a
similar 4-week HIIT program [47].
The standard deviation for the change in V

O2peak in the
current study is 6.36% or 235.8 mL ∙ min−1, similar to the
value of 202 mL ∙ min−1 in the HERITAGE study [1]. Fur-
thermore, in a recent meta-analysis, changes in V

O2peak
after endurance and HIIT training were reported to range
from −455 to 1521 mL ∙ min−1 [48]. In the current study,
our preliminary results show a range of −280.69 to
629.25 mL ∙ min−1. Once again, the lower upper limit can
probably be attributed to the relatively short duration of
Fig. 3 Percentage change of peak oxygen uptake and peak aerobic power after 4 wk. of High Intensity Interval Training (HIIT) as compared with
the individual baseline measures (n = 39). a Change of peak oxygen uptake after HIIT in percentage; b Change of peak aerobic power after HIIT
in percentage
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the training program, and relatively high baseline fitness of
the participants, in our study compared to many of the
studies included in the meta-analysis. Nonetheless, our re-
sults support previous research indicating there is consid-
erable individual variability for training-induced changes in
V

O2peak.
All other physiological and performance indicators
improved significantly after 4wk of HIIT. Figure 3b
shows an improvement of 6.80 ± 4.82% Wpeak
(Mean ± SD, p < 0.001), which is consistent with the ~8%
increase reported when using similar training protocols
[35, 36]. The 9.01 ± 6.66% increase in LT after 4 weeks of
HIIT (Fig. 4a, Mean ± SD, p < 0.001), is also similar to the
7 to 8% increase previously reported in response to similar
training [35, 36]. Figure 4b shows that, on average, partici-
pants improved their 20 km-TT by 3.34 ± 4.46%
(Mean ± SD, p < 0.001), consistent with previously re-
ported improvements in this parameter [36]. Thus, our
training program was effective to increase common mea-
sures of aerobic fitness and endurance performance.
While previous studies regarding the individual re-
sponses to exercise mainly focused on V

O2peak or V

O2max,
the gene SMART study is also looking at individual re-
sponses in other performance variables, such as Wpeak, LT
and 20 km-TT. The standard deviation for the change in
these variables with training was 4.82% for Wpeak, 6.66%
for LT and 4.46% for 20 km-TT. While no previous study
has specifically investigated individual responses of these
variables, our mean, SD, range etc., are consistent with
other small-scale training studies [36, 47]. Furthermore,
these values are consistent with the SD reported for the
training-induced change in V

O2max in the HERITAGE
study (~7%; [1]).
An additional novel aspect of the gene SMART study
is the investigation of individual responses at the skeletal
muscle level. Figure 5a shows an average increase of
13.10 ± 18.02% (Mean ± SD, p = 0.004) in citrate syn-
thase activity (a valid indicator of mitochondrial content
[49]). The increase is greater than what we have reported
when using a similar training program (7.5%, [36]), but
less than the 28% increase reported following 6 week of
HIIT (10 × 4 min intervals at 90% peak oxygen con-
sumption separated by 2 min rest, 3 days per week [50]).
Of note, we have previously reported that training vol-
ume appears to be an important determinant of
training-induced changes in CS activity [8], and this may
help to explain the differences between studies. More
importantly, we have observed considerable variability
for the training-induced change in CS activity
(SD = 18.02%; Fig. 5a). With the gene SMART study, we
plan to investigate the possible contribution of genetic
factors to this variability.
Fig. 4 Percentage change of lactate threshold and 20-km time trial after 4 wk. of HIIT as compared with the individual baseline measures
(n = 39). a Change of lactate threshold after HIIT in percentage; b Change of 20-km time trial after HIIT in percentage
The Author(s) BMC Genomics 2017, 18(Suppl 8):821 Page 25 of 131
Similar to what we have reported before [36, 47], we
did not observe significant changes in maximal, ADP-
stimulated mitochondrial respiration (an indicator of
mitochondrial function), after 4 week of HIIT (Fig. 5b,
9.28 ± 21.27%, Mean ± SD, p = 0.47). Of note, even
though the mean value for maximal ADP-stimulated
mitochondrial respiration was not different after four
wk. of HIIT, there were some individuals who increased
mitochondrial respiration by more than 50%, while
others decreased by approximately 20%, which clearly
indicates high individual variability in this particular
phenotype in response to similar exercise training. The
possible contribution of genetic factors to this variability
warrants further investigation.
Conclusions
Even though the gene SMART study is tightly con-
trolled, we still observe significant variability in both per-
formance (in-vivo) and muscle (in-situ) adaptations to
similar training However, while the preliminary data sug-
gest considerable variability in the response of physio-
logical, muscle and performance related factors to
4 weeks of HIIT, more participants are required to allow
us to better investigate potential underlying genetic and
molecular mechanisms. More participants are being
recruited to give us the statistical power to investigate
both specific (hypothesis-driven) and non-specific
(hypothesis-free) genetic variants as possible predictors,
and to follow up these results with the analysis of appro-
priate molecular/cellular pathways.
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